Nei gomarara richiendeswa zviri nyore kuchiropa?

Share This Post

A Duke University study has shown that metastatic cancer cells can regulate the metabolic function to reproduce in new organs. Cells derived from colorectal cancer have changed their metabolic habits, making full use of fructose in the liver as much as possible. Once the cancer has spread to different parts of the body, the cancer becomes more deadly, but the treatment does not consider the location of its metastasis and is treated according to the original site. From a genetic point of view, kenza yemaroni is colon cancer, no matter where it is transferred. But this does not mean that it cannot respond to the new environment. This response may not be genetic, but metabolic. When cancer cells enter the liver, they are like a child in a candy store, using this abundant new energy to create more cancer cells. In order to feed on fructose, cancer cells need to produce more enzymes that can break down fructose, called ALDOB. Once cancer cells find out how to turn fructose back on, cancer cells will lose control and proliferate. In addition to providing reasons for how cancer proliferates after metastasis, this discovery can also lead to new therapies for metastatic cells. For example, avoiding the use of fructose by eating natural non-processed foods and providing drugs that block the metabolism of fructose may prevent cancer from spreading from other organs to the liver. Since pharmaceutical companies have recently developed new drugs for fructose metabolism to treat metabolic diseases, this crossover therapy may not be far away. Doctors can usually remove the primary tumor. But understanding the causes of cancer metastasis and how to adapt to a new home may provide us with a new weapon against cancer.

Subscribe To Newsletter Vedu

Wana zvigadziriso uye usambopotsa blog kubva kuCancerfax

Zvimwe Kuti Uongorore

Lutetium Lu 177 dotatate inotenderwa neUSFDA kune vana vane makore gumi nemaviri zvichikwira neGEP-NETS.
kenza

Lutetium Lu 177 dotatate inotenderwa neUSFDA kune vana vane makore gumi nemaviri zvichikwira neGEP-NETS.

Lutetium Lu 177 dotatate, kurapwa kwepasi, ichangobva kugamuchira mvumo kubva kuUS Food and Drug Administration (FDA) yevarwere vevana, zvichiratidza chiitiko chakakosha muvana oncology. Mvumo iyi inomiririra chiedza chetariro kuvana vari kurwisana neuroendocrine tumors (NETs), isingawanzowanikwi asi inonetsa yegomarara iro rinowanzoratidza kuti rinoshingirira pakurapa kwakajairika.

Nogapendekin alfa inbakicept-pmln inotenderwa neUSFDA yeBCG-isingapindure isiri-muscle invasive cancer cancer.
Chirwere chechirwere

Nogapendekin alfa inbakicept-pmln inotenderwa neUSFDA yeBCG-isingapindure isiri-muscle invasive cancer cancer.

"Nogapendekin Alfa Inbakicept-PMLN, chinyorwa che immunotherapy, chinoratidza vimbiso mukurapa gomarara redundira kana yasanganiswa neBCG therapy. Iyi nzira yekuvandudza yakanangana nemakaki egomarara uku ichisimudzira mhinduro ye immune system, ichiwedzera kushanda kwemishonga yechivanhu seBCG. Miedzo yemakiriniki inoratidza zvinokurudzira, zvichiratidza zvakavandudzwa mhedzisiro yemurwere uye kufambira mberi kunogona kuitika mukurapa kenza yedundira. Kuwirirana pakati peNogapendekin Alfa Inbakicept-PMLN neBCG kunozivisa nguva itsva mukurapa gomarara redundira.

Kuda rubatsiro? Chikwata chedu chakagadzirira kukubatsira.

Tinoshuvira kupora nekukurumidza kwemudiwa wako uye padyo neuyo.

Kutanga kutaura
Tiri paIndaneti! Taura Nesu!
Skena kodhi
Mhoro,

Kugamuchirwa kuCancerFax!

CancerFax ipuratifomu yekupayona yakatsaurirwa kubatanidza vanhu vakatarisana negomarara repamberi nekurapa kwesero seCAR T-Cell therapy, TIL kurapwa, uye miedzo yekiriniki pasi rese.

Tizivise zvatinogona kukuitira.

1) Kurapwa kwegomarara kunze kwenyika?
2) CAR T-Cell therapy
3) Mushonga wegomarara
4) Online vhidhiyo kubvunza
5) Proton kurapwa